Car-Nk-Cd19 Cells
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Explore 203 assets in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma →Floatz Rating
C37/100
Confidence
Indicative
Sponsor
Beijing Boren Hospital
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05410041CT.gov Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | — | Unknown | — | — | — |
NCT04796675CT.gov Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | — | Unknown | — | — | — |
NCT04796688CT.gov Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Car-Nk-Cd19 Cells (this asset) | Beijing Boren Hospital | P1 | C · 37 |
| Chlorambucil | Ascentage Pharma Group Inc. | P4 | BBB |
| Etoposide | Weill Medical College of Cornell University | P2 | BBB |
| Lisaftoclax | Henan Cancer Hospital | P3 | BBB |
| Irinotecan | IGM Biosciences, Inc. | P2 | BBB |
| Prednisone | AstraZeneca | P3 | BBB |
| Rituximab | M.D. Anderson Cancer Center | P4 | BB |
| Alvocidib | Sanofi | P2 | BB |
| Ppsv23 | Region Örebro County | P4 | BB |
+42 more in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort
Other indications for Car-Nk-Cd19 Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Mediastinal Large B-Cell Lymphoma | — | P1 | CC · 43 |
| Diffuse Large B-Cell Lymphoma | — | P1 | CC · 43 |
| Mantle Cell Lymphoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Car-Nk-Cd19 Cells in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/car-nk-cd19-cells-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →